Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 5.4 %

Shares of OGEN stock opened at $0.28 on Wednesday. The stock has a 50-day moving average of $0.34 and a 200-day moving average of $0.61. The stock has a market cap of $3.44 million, a price-to-earnings ratio of -0.04 and a beta of 0.40. Oragenics has a 1-year low of $0.25 and a 1-year high of $5.63.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.